Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of HPV, promising new screening approaches using HPV DNA testing, and the recent licensure of the first prophylactic HPV vaccine targeting the two most common high-risk types of HPV, 16 and 18. We propose to refine our Cervical Cancer Screening Model to be capable of assessing the costs, benefits, and cost-effectiveness of primary prevention (vaccination), secondary prevention (screening), and strategies that combine both.
Our specific aims are: (1) to refine a natural history model to function as an open population- based simulation model capable of forecasting incidence, mortality, and costs associated with different cervical cancer control strategies. This model will be calibrated to the United States population using the best available data, including observed patterns in HPV type-specific prevalence, invasive cancer, and temporal variation in factors such as sexual behavior and smoking; (2) to develop a dynamic transmission model of HPV 16 and 18 to estimate the population-level impact of a type-specific vaccination taking into account biological and host factors, vaccine properties, behavioral issues, and herd immunity. We will assess the incremental benefit of vaccinating boys in addition to girls under different scenarios; compare the costs and benefits of policies restricting vaccination to young girls not yet sexually active with policies extending vaccination to women in their late 20s; explore how uncertain assumptions about sexual mixing patterns affect results; and project temporal trends in type-specific HPV prevalence; (3) to assess the cost-effectiveness of alternative cervical cancer prevention strategies for a the general U.S. population as well as for subgroups that differ in their socioeconomic, demographic, and cervical cancer risk profile. We will explore how the cost-effectiveness of a combined screening and vaccination program could change over time, evaluate the effect of vaccination on the test performance of current HPV diagnostics; and assess how vaccine delivery (target age, upper age limit, coverage by age and risk group), vaccine characteristics, and programmatic features influence projected benefits and cost-effectiveness. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA093435-04A1
Application #
7372593
Study Section
Health Services Organization and Delivery Study Section (HSOD)
Program Officer
Brown, Martin L
Project Start
2002-05-07
Project End
2010-07-31
Budget Start
2007-09-27
Budget End
2008-07-31
Support Year
4
Fiscal Year
2007
Total Cost
$369,929
Indirect Cost
Name
Harvard University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Campos, Nicole G; Kim, Jane J; Castle, Philip E et al. (2012) Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 130:2672-84
Burger, E A; Ortendahl, J D; Sy, S et al. (2012) Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106:1571-8
Goldie, Sue J; O'Shea, Meredith; Kim, Jane J (2012) Finding consensus on cervical cancer prevention. Am J Public Health 102:1050-1; author reply 1051
Campos, Nicole G; Castle, Philip E; Schiffman, Mark et al. (2012) Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. Med Decis Making 32:400-27
Price, Rebecca Anhang; Frank, Richard G; Cleary, Paul D et al. (2011) Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. Med Care 49:132-8
Goldie, Sue J; Daniels, Norman (2011) Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst 103:1373-86
Campos, Nicole G; Rodriguez, Ana Cecilia; Castle, Philip E et al. (2011) Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis 203:823-7
Goldhaber-Fiebert, Jeremy D; Stout, Natasha K; Goldie, Sue J (2010) Empirically evaluating decision-analytic models. Value Health 13:667-74
Kim, Jane J (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10:845-52
Kim, Jane J; Ortendahl, Jesse; Goldie, Sue J (2009) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 151:538-45

Showing the most recent 10 out of 35 publications